Ordering
Available Variants10 mg
CHA.96079-10mg
Price
€100.00
Available – Dispatch in 14 days
100 mg
CHA.96079-100mg
Price
€565.76
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.96079-10mg | €100.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHA.96079-100mg | €565.76 |
≥98% (HPLC), powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C13H10N2O4 |
|---|---|
| CAS Number | 2614-06-4 |
| Molecular Weight | 258.23 |
| NACRES | NA.77 |
| PubChem Substance ID | 24899975 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD00210220 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Danger |
| hcodes | H302,H360 |
| pcodes | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Oral - Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
(+)-Thalidomide, with the CAS number 2614-06-4, is a synthetic compound that has garnered significant attention in the scientific community due to its unique properties and applications. Initially developed as a sedative, it was later found to possess immunomodulatory and anti-angiogenic effects, making it a valuable therapeutic agent in the treatment of certain diseases, including multiple myeloma and erythema nodosum leprosum. The (+) enantiomer of thalidomide has been shown to exhibit distinct pharmacological activities compared to its (-) counterpart, highlighting the importance of stereochemistry in its mechanism of action. As a result, researchers have been actively investigating the potential benefits and risks associated with (+)-thalidomide, with a focus on optimizing its therapeutic efficacy while minimizing adverse effects, ultimately aiming to expand its clinical utility and improve patient outcomes. Further studies are necessary to fully elucidate its complex pharmacology.
